Kim A. Reiss

Kim A. Reiss, MD is an Associate Professor of Medicine specializing in Hematology-Oncology at the University of Pennsylvania's Perelman School of Medicine and a physician at the Abramson Cancer Center. She serves as Assistant Program Director of the Hematology/Oncology Fellowship Program and maintains active hospital privileges at the Hospital of the University of Pennsylvania, accepting new patients aged 18+ with high patient satisfaction ratings (5.0/5.0 from 362 reviews).

Her educational background includes:

• Medical School: Pennsylvania State University College of Medicine
• Residency: Johns Hopkins Hospital
• Fellowship: Johns Hopkins Hospital

Dr. Reiss's research focuses on advancing cancer treatment through genetics and immunotherapy, with particular emphasis on pancreatic cancer and solid tumors. Her work investigates liquid biopsy accuracy for detecting genetic variants, homologous recombination repair deficiencies, and novel therapeutic approaches including CAR-macrophage therapy and targeted agents like zenocutuzumab. She actively explores how clonal hematopoiesis impacts variant interpretation in advanced cancers.

Analysis of her 2025 publications reveals strong trends in translational oncology research, with significant contributions to understanding BRCA/PALB2 variants in pancreatic cancer, developing rucaparib-based treatments for HR-deficient tumors, and pioneering cellular immunotherapies. Her work bridges genomic discoveries with clinical applications across multiple high-impact studies.

As Assistant Program Director of the Fellowship Program, Dr. Reiss mentors oncology fellows in both clinical practice and research methodology. Her active grant portfolio supports multiple clinical trials including the LODESTAR study, pancreatic cancer combination therapy research, and first-in-human CAR-macrophage trials, providing substantial resources for translational research.

Dr. Reiss leads a collaborative research team focused on cancer genetics and immunotherapy within the Abramson Cancer Center infrastructure. Her group actively participates in multi-institutional studies and leverages Penn Medicine's comprehensive cancer center resources for translational research from bench to bedside.